Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 2
2013 1
2017 1
2018 1
2019 4
2020 3
2021 3
2022 8
Text availability
Article attribute
Article type
Publication date

Search Results

21 results
Results by year
Filters applied: . Clear all
Page 1
CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.
Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, Scarfó I, Leick MB, Grauwet K, Berger TR, Stewart K, Anekal PV, Jan M, Joung J, Schmidts A, Ouspenskaia T, Law T, Regev A, Getz G, Maus MV. Larson RC, et al. Among authors: leick mb. Nature. 2022 Apr;604(7906):563-570. doi: 10.1038/s41586-022-04585-5. Epub 2022 Apr 13. Nature. 2022. PMID: 35418687
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity.
Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, Bailey SR, Boroughs AC, Frigault MJ, Leick MB, Scarfò I, Cetrulo CL, Demehri S, Nahed BV, Cahill DP, Wakimoto H, Curry WT, Carter BS, Maus MV. Choi BD, et al. Among authors: leick mb. Nat Biotechnol. 2019 Sep;37(9):1049-1058. doi: 10.1038/s41587-019-0192-1. Epub 2019 Jul 22. Nat Biotechnol. 2019. PMID: 31332324
CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.
Choi BD, Yu X, Castano AP, Darr H, Henderson DB, Bouffard AA, Larson RC, Scarfò I, Bailey SR, Gerhard GM, Frigault MJ, Leick MB, Schmidts A, Sagert JG, Curry WT, Carter BS, Maus MV. Choi BD, et al. Among authors: leick mb. J Immunother Cancer. 2019 Nov 14;7(1):304. doi: 10.1186/s40425-019-0806-7. J Immunother Cancer. 2019. PMID: 31727131 Free PMC article.
Telephone.
Leick MB. Leick MB. N Engl J Med. 2020 Dec 10;383(24):2304-2305. doi: 10.1056/NEJMp2016673. Epub 2020 Aug 19. N Engl J Med. 2020. PMID: 32813943 No abstract available.
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, Depinho GD, Katsis K, Elder EL, Leick MB, Choi B, Horick N, Preffer F, Saylor M, McAfee S, O'Donnell PV, Spitzer TR, Dey B, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB. Frigault MJ, et al. Among authors: leick mb. Blood. 2022 Apr 14;139(15):2306-2315. doi: 10.1182/blood.2021014738. Blood. 2022. PMID: 35167655 Clinical Trial.
Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS).
Wehrli M, Gallagher K, Chen YB, Leick MB, McAfee SL, El-Jawahri AR, DeFilipp Z, Horick N, O'Donnell P, Spitzer T, Dey B, Cook D, Trailor M, Lindell K, Maus MV, Frigault MJ. Wehrli M, et al. Among authors: leick mb. J Immunother Cancer. 2022 Jan;10(1):e003847. doi: 10.1136/jitc-2021-003847. J Immunother Cancer. 2022. PMID: 34996813 Free PMC article.
Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.
Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarfò I, Kann MC, Berger TR, Leick MB, Wehrli M, Schmidts A, Silva H, Lindell KA, Demato A, Gallagher KME, Frigault MJ, Maus MV. Bailey SR, et al. Among authors: leick mb. Blood Cancer Discov. 2022 Mar 1;3(2):136-153. doi: 10.1158/2643-3230.BCD-21-0181. Blood Cancer Discov. 2022. PMID: 35015685 Free PMC article.
Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma.
Haradhvala NJ, Leick MB, Maurer K, Gohil SH, Larson RC, Yao N, Gallagher KME, Katsis K, Frigault MJ, Southard J, Li S, Kann MC, Silva H, Jan M, Rhrissorrakrai K, Utro F, Levovitz C, Jacobs RA, Slowik K, Danysh BP, Livak KJ, Parida L, Ferry J, Jacobson C, Wu CJ, Getz G, Maus MV. Haradhvala NJ, et al. Among authors: leick mb. Nat Med. 2022 Sep;28(9):1848-1859. doi: 10.1038/s41591-022-01959-0. Epub 2022 Sep 12. Nat Med. 2022. PMID: 36097221
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.
Miller PG, Sperling AS, Brea EJ, Leick MB, Fell GG, Jan M, Gohil SH, Tai YT, Munshi NC, Wu CJ, Neuberg DS, Maus MV, Jacobson C, Gibson CJ, Ebert BL. Miller PG, et al. Among authors: leick mb. Blood Adv. 2021 Aug 10;5(15):2982-2986. doi: 10.1182/bloodadvances.2021004554. Blood Adv. 2021. PMID: 34342642 Free PMC article.
21 results